NCT02140554View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 2, 2015

Primary Completion Date

July 31, 2023

Study Completion Date

January 30, 2024

Conditions
Sickle Cell Disease
Interventions
GENETIC

lovo-cel

lovo-cel is administered by IV infusion following myeloablative conditioning with busulfan.

Trial Locations (11)

30322

Atlanta

Unknown

Birmingham

Oakland

Chicago

Bethesda

Hackensack

New Hyde Park

New York

Chapel Hill

Philadelphia

Charleston

Sponsors
All Listed Sponsors
lead

Genetix Biotherapeutics Inc.

INDUSTRY